Keyword: Opsumit

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

Could Actelion's $26 billion-plus deal talks with J&J fall through, now that its PAH drug Opsumit has fallen short in a study designed to grow its market? Not likely, analysts said Monday.

CVS Health raised some hackles with a 2017 formulary that barred the world’s top-selling basal insulin, blocked two cancer treatments, and excluded two pricey orphan drugs. Should drugmakers be afraid?

Bayer has long counted pulmonary arterial hypertension newcomer Adempas among its Big 5 growth products. But should it?